Table 1. Demographic and clinical characteristics of all study subjects.
| Variable | Value (n=160) |
|---|---|
| Age (y) | 68.4/69.7 (45–79) |
| Clinical stage | |
| T1c | 117 (73.1) |
| ≥T2 | 43 (26.9) |
| Prostate volume (mL) | 32.2/33.3 (12–96) |
| tPSA (ng/mL) | 11.7/7.7 (3.5–74.9) |
| p2PSA | 26.4/18.4 (0.7–189.6) |
| %fPSA | 0.14/0.12 (0.01–1.27) |
| %p2PSA | 1.92/1.69 (0.62–7.3) |
| PSA density | 0.28 (0.26) |
| PHI | 67.1/47.2 (19.5–360.9) |
| Biopsy Gleason sum | |
| 6 | 98 (61.3) |
| 7 (3+4) | 20 (12.5) |
| 7 (4+3) | 33 (20.6) |
| ≥8 | 9 (5.6) |
| Number of positive biopsy core | 3.2/3 (1–12) |
| Maximal percentage in each biopsy core (%) | 45.2/39.5 (4.6–99.9) |
| Pathology Gleason sum | |
| 6 | 64 (40.0) |
| 7 (3+4) | 50 (31.3) |
| 7 (4+3) | 31 (19.4) |
| ≥8 | 15 (9.4) |
| Gleason upgrading | 34 (21.3) |
| Tumor stage | |
| T2 | 79 (49.4) |
| T3a | 76 (47.5) |
| T3b | 5 (3.1) |
| Resection margin | |
| Negative | 130 (81.3) |
| Positive | 30 (18.8) |
Values are presented as mean/median (range), mean (median), or number (%).
PSA, prostate specific antigen; tPSA, total PSA; fPSA, free PSA; p2PSA, [−2]proPSA; %fPSA, percentage of fPSA to tPSA; %p2PSA, percentage of p2PSA to tPSA; PHI, prostate health index.